Company Announcement <li /> Johnson & Johnson has decided that it will not exercise its option to receive a ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.

infusion-related reactions, anemia and thrombocytopenia. One patient died from a TEAE in the HexaBody-CD38 arm, while two patients died in the daratumumab arm; the three deaths were not related to ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Treatment emergent Adverse events (TEAEs) above 20% in the Hexabody-CD38 arm were neutropenia, infusion related reactions, anemia, and thrombocytopenia. No new safety findings were observed in the ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...